TYRO3 and prostate cancer: Using a subcutaneous model of prostate cancer from which tumor cells disseminate to the bone, bone marrow DTCs exhibited reduced proliferation, which was associated with increased Axl and reduced tyro3 expression in comparison to the primary tumor.